Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19531499 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Tong J, et al. (2009) Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041. Mol Cell Proteomics 8, 2131-44 19531499
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T693-p - EGFR (human) ▲
Orthologous residues
EGFR (human): T693‑p, EGFR (mouse): T695‑p, EGFR (rat): T694‑p, EGFR (pig): T693‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

S991-p - EGFR (human) ▲
Orthologous residues
EGFR (human): S991‑p, EGFR (mouse): S993‑p, EGFR (rat): S992‑p, EGFR (pig): S991‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation, phosphorylation, receptor internalization, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
ubiquitin (human) Induces co-immunoprecipitation
Cbl (human) Induces co-immunoprecipitation
 Comments:  mutation of this site increases phosphorylation of EGFR S1039, T1041 and Y1092

Y998-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y998‑p, EGFR (mouse): Y1000‑p, EGFR (rat): Y999‑p, EGFR (pig): Y998‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation, phosphorylation, receptor internalization, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Cbl (human) Induces co-immunoprecipitation
 Comments:  mutation of this site increases phosphorylation of EGFR S1039, T1041 and Y1092

S1026-p - EGFR (human) ▲
Orthologous residues
EGFR (human): S1026‑p, EGFR (mouse): S1028‑p, EGFR (rat): S1027‑p, EGFR (pig): S1026‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

S1037-p - EGFR (human) ▲
Orthologous residues
EGFR (human): S1037‑p, EGFR (mouse): S1039‑p, EGFR (rat): S1038‑p, EGFR (pig): S1037‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

S1039-p - EGFR (human) ▲
Orthologous residues
EGFR (human): S1039‑p, EGFR (mouse): S1041‑p, EGFR (rat): S1040‑p, EGFR (pig): S1039‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38B (human) pharmacological inhibitor of upstream enzyme
KINASE P38A (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGFR (human) increase EGFR Y998F/S991A mutant
EGF increase
SB202190 EGF inhibit treatment-induced increase

T1041-p - EGFR (human) ▲
Orthologous residues
EGFR (human): T1041‑p, EGFR (mouse): T1043‑p, EGFR (rat): N1042‑p, EGFR (pig): T1041‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) pharmacological inhibitor of upstream enzyme
KINASE P38B (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGFR (human) increase EGFR Y998F/S991A mutant
EGF increase
SB202190 EGF inhibit treatment-induced increase

S1042-p - EGFR (human) ▲
Orthologous residues
EGFR (human): S1042‑p, EGFR (mouse): S1044‑p, EGFR (rat): S1043‑p, EGFR (pig): S1042‑p

Y1069-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1069‑p, EGFR (mouse): Y1069‑p, EGFR (rat): Y1068‑p, EGFR (pig): Y1068‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

S1081-p - EGFR (human) ▲
Orthologous residues
EGFR (human): S1081‑p, EGFR (mouse): N1081‑p, EGFR (rat): N1080‑p, EGFR (pig): S1080‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

T1085-p - EGFR (human) ▲
Orthologous residues
EGFR (human): T1085‑p, EGFR (mouse): A1085‑p, EGFR (rat): T1084‑p, EGFR (pig): T1084‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

Y1092-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1092‑p, EGFR (mouse): Y1092‑p, EGFR (rat): Y1091‑p, EGFR (pig): Y1091‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase

S1096-p - EGFR (human) ▲
Orthologous residues
EGFR (human): S1096‑p, EGFR (mouse): S1096‑p, EGFR (rat): S1095‑p, EGFR (pig): S1095‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

S1104-p - EGFR (human) ▲
Orthologous residues
EGFR (human): S1104‑p, EGFR (mouse): S1104‑p, EGFR (rat): S1103‑p, EGFR (pig): S1103‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

Y1110-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1110‑p, EGFR (mouse): Y1110‑p, EGFR (rat): Y1109‑p, EGFR (pig): Y1109‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

Y1138-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1138‑p, EGFR (mouse): Y1138‑p, EGFR (rat): Y1137‑p, EGFR (pig): Y1137‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

S1166-p - EGFR (human) ▲
Orthologous residues
EGFR (human): S1166‑p, EGFR (mouse): S1166‑p, EGFR (rat): S1165‑p, EGFR (pig): N1165‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

Y1172-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1172‑p, EGFR (mouse): Y1172‑p, EGFR (rat): Y1171‑p, EGFR (pig): Y1171‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human

Y1197-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1197‑p, EGFR (mouse): Y1197‑p, EGFR (rat): Y1196‑p, EGFR (pig): Y1196‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.